Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

155.06 -0.32 (-0.21%)
Streaming Delayed Price Updated: 10:31 AM EDT, Apr 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
3 Dividend Kings That Have Raised Their Payouts in 2025
Via The Motley Fool
Topics Economy
Exposures Interest Rates
In the Wake of the Trump Tariff Crash: 2 Unparalleled Dividend Stocks to Buy at a Discount Right Now
Short-term tariff uncertainty marks the perfect opportunity for long-term investors to snag some amazing deals. 
Via The Motley Fool
Topics Economy Government Stocks
Exposures Interest Rates Political Tariff
Merck (MRK) Reports Q1: Everything You Need To Know Ahead Of Earnings
Global pharmaceutical company Merck (NYSE:MRK) will be reporting results tomorrow before market hours. Here’s what to expect. 
Via StockStory
Bristol-Myers Squibb (BMY) Reports Earnings Tomorrow: What To Expect
Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) will be announcing earnings results tomorrow morning. Here’s what investors should know. 
Via StockStory
Trump Administration Considers Lowering US Drug Prices To International Levels: Report
The Trump Administration is reportedly mulling over a policy to match U.S. drug prices with those in other developed nations. 
Via Benzinga
Topics Government
Exposures Political
JNJ Q1 Earnings: Pipeline Progress and MedTech Execution Drive Guidance Above Expectations
Multinational healthcare company Johnson & Johnson (NYSE:JNJ) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 2.4% year on year to $21.89 billion. The company’s full-year revenue... 
Via StockStory
Topics Earnings World Trade
Exposures Financial Tariff
Why Johnson & Johnson, Chevron, And Flowers Foods Are Winners For Passive Income
Via Benzinga
Roche Plans $50 Billion US Investment Over 5 Years With 12,000 New Jobs
Roche to invest $50 billion in U.S. over five years, adding 12,000+ jobs and expanding manufacturing, R&D, and export capacity across eight states. 
Via Benzinga
9 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Johnson & Johnson (JNJ): Buy, Sell, or Hold Post Q1 Earnings?
Johnson & Johnson has been treading water for the past six months, recording a small loss of 3.8% while holding steady at $157.30. However, the stock is beating the S&P 500’s 11% decline during that... 
Via StockStory
Topics Stocks
Exposures US Equities
2 Recession-Proof Stocks to Buy With a Better Credit Rating Than the U.S. Government
Via The Motley Fool
Topics Artificial Intelligence Economy Government
Exposures Artificial Intelligence Economy Political
From $50 A Month To $1M Portfolio — Investor Shares Top 10 Holdings, Says 'Finally Reached $1M!' Thanks To Relentless Discipline
Via Benzinga
Stocks That Weathered Past Recessions: Expert Shares Picks That Withstood Every Downturn
Stock market expert Jon Erlichman recently shared a review of stock returns during the last six U.S. recessions, highlighting those that have performed well in difficult times. 
Via Benzinga
The SWAN (Sleep Well At Night) Blueprint Revealed
I’ve adopted “SWAN,” which stands for 
Via Talk Markets
Topics Stocks / Equities
3 Top Dividend Stocks Yielding Over 3% to Buy With $500 Right Now
Via The Motley Fool
Topics Bonds
Exposures Debt Markets
ETF Shake-Up: UNH's Meltdown Meets LLY's Moonshot
Healthcare sector sees volatility due to UnitedHealth's earnings disappointment, but ETFs like XLV, IHE, and XPH still show resilience and pockets of strength. 
Via Benzinga
Topics ETFs
Where Will Eli Lilly Be in 5 Years?
Via The Motley Fool
How To Put $100 In Your Retirement Fund Each Month With Johnson & Johnson Stock
Via Benzinga
Topics Retirement
Exposures Pension
4 Reasons Johnson & Johnson Could Be the Perfect Stock to Own in Today's Turbulent Market
Via The Motley Fool
Topics Earnings Government World Trade
Exposures Financial Political Tariff
This Super-Safe High-Yield Stock Just Extended Its Dividend Growth Streak to 63 Years in a Row
Via The Motley Fool
Topics Bonds
Exposures Debt Markets
Buy These Defensive Stocks After Beating Earnings Expectations?: ACI, JNJ
Johnson & Johnson and Albertsons Companies' stock have provided a pleasant hedge against market volatility, with the S&P 500 and Nasdaq remaining near correction territory. 
Via Talk Markets
Topics Stocks Stocks / Equities
Exposures US Equities
Healthcare Sector Update: MEDtech And Diagnostics
Amidst the tariff chaos, we may get clues from one of the most defensive sectors of the market-healthcare stocks. 
Via Talk Markets
Topics ETFs Stocks / Equities World Trade
Exposures Tariff
Johnson & Johnson to Participate in the 2025 RBC Capital Markets Global Healthcare Conference
From Johnson & Johnson
Via Business Wire
Trump's New Order Targets Drug Pricing Transparency And Medicare Cost Reduction
Trump orders multi-part executive order to lower drug prices, reduce Medicare costs. Includes guidance on Medicare drug prices, aligning payments with hospital acquisition costs, and investigating... 
Via Benzinga
Topics Government
Exposures Political
How Is The Market Feeling About Johnson & Johnson?
Via Benzinga
Johnson & Johnson's Q1 Results, FY Guidance Highlight The 'Power Of The Pharma Portfolio'
Johnson & Johnson (JNJ) reported upbeat Q1 results amid an exciting earnings season, with analysts noting impressive sales and guidance from the pharma giant. 
Via Benzinga
Johnson & Johnson Earnings Were More Good Than Bad—Time to Buy?
Johnson & Johnson had more good than bad; investors should look at the entire report in context before deciding if JNJ stock is a good fit for their portfolios 
Via MarketBeat
Topics Government Intellectual Property World Trade
Exposures Intellectual Property Political Tariff
Johnson & Johnson Q1 Earnings: Strong Cancer Drug Sales, Boosts Quarterly Dividend, Anticipates Negative Currency Impact For 2025 Profit
Johnson & Johnson raised its 2025 sales outlook and dividend, while Q1 results topped expectations driven by strong cancer drug performance. 
Via Benzinga
2 Under-the-Radar Consumer Staples Stocks With Big Dividends
Edgewell and Kenvue are under-the-radar consumer staples stocks poised to gain as the U.S. dollar declines. Learn why they may boost your income portfolio. 
Via MarketBeat
Topics ETFs Intellectual Property World Trade
Exposures Intellectual Property Tariff
Johnson & Johnson Skids Despite First-Quarter Beat, Sales Guidance Hike
Johnson & Johnson stock fell alongside the broader market, despite beating first-quarter calls and hiking its sales outlook. 
Via Investor's Business Daily
Topics Government Stocks
Exposures Political US Equities
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.